Results 181 to 190 of about 13,157 (218)

Changes in the Use of Montelukast for Asthma After a US Food and Drug Administration Boxed Warning.

JAMA Netw Open
Shanmugam H, Kesselheim AS, Liu ITT, Feldman WB, Rome BN.   +4 more
europepmc   +1 more source

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
openaire  

Onset of Effect of Aclidinium, a Novel, Long-Acting Muscarinic Antagonist, in Patients with COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease, 2010
ABSTRACT Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). The aim of this study was to assess the rate of onset of bronchodilation with aclidinium compared with placebo and tiotropium.
Jørgen Vestbo, Claus F Vogelmeier, Meritxell Falqués   +2 more
exaly   +6 more sources

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients [PDF]

Respiratory Medicine, 2010
Aclidinium bromide is a novel, long-acting, inhaled muscarinic antagonist bronchodilator currently in Phase III clinical development for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the pharmacodynamics, pharmacokinetics, safety and tolerability of ascending doses of aclidinium bromide in patients with COPD.This ...
G F Joos, F Kanniess, E Garcia Gil
exaly   +4 more sources

NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease

Therapeutic Advances in Respiratory Disease, 2011
Bronchodilation with a long-acting muscarinic antagonist (LAMA) or long-acting β 2 -agonist is central to the management of chronic obstructive pulmonary disease (COPD).
Claus F Vogelmeier, Donald Banerji
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Current long-acting muscarinic antagonists for the treatment of asthma

Expert Opinion on Pharmacotherapy, 2021
The role of long-acting muscarinic antagonists (LAMAs) is well established in uncontrolled asthma, but not in milder stages.This review examines the main randomized controlled trials (RCTs) that have investigated LAMAs administered as monotherapy or in combination to asthmatic patients, according to the different phenotypes.
Ora J., Calzetta L., Ritondo B. L., Matera M. G., Rogliani P.   +4 more
openaire   +3 more sources

Tiotropium bromide, a long acting muscarinic receptor antagonist triggers intracellular calcium signalling in the heart [PDF]

Toxicology and Applied Pharmacology, 2019
Background and purpose: Tiotropium bromide (TB) is a long acting muscarinic receptor antagonist used to manage chronic obstructive pulmonary disease (COPD). Recent meta-analyses suggest an increased risk of cardiovascular events with TB.
Shabana Cassambai, Derek Renshaw, Afthab Hussain   +2 more
exaly   +2 more sources